Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data

scientific article

Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1469-0691.1996.TB00197.X
P698PubMed publication ID11866808
P5875ResearchGate publication ID11494983

P2093author name stringM. Cruciani
G. Gatti
A. Benini
A. Cazzadori
D. Bassetti
E. Bertazzoni Minelli
E. Concia
G. Piemonte
L. Lazzarini
M. Malena
M. Merighi
M. Mirandola
R. Luzzati
R. Mazzi
S. Vento
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectpharmacokineticsQ323936
dapsoneQ422226
Pneumocystis cariniiQ2099992
P304page(s)30-35
P577publication date1996-08-01
P1433published inClinical Microbiology and InfectionQ15757285
P1476titleTwice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data
P478volume2

Reverse relations

cites work (P2860)
Q35136075Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients
Q40092648Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.